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INTRODUCTION
In mammalian organisms a reduction in cellular or systemic levels of O 2 (hypoxia) induces a coordinated cascade of biological responses. A critical regulator of these responses to hypoxia is the hypoxia-inducible factor-1α (HIF-1α 1 ). Together with a partner factor, Arnt, HIF-1α forms in the nucleus of hypoxic cells a heterodimeric complex of basic-helix-loop-helix (bHLH) / Per, Arnt and Sim (PAS) domain proteins that activates transcription of a network of genes encoding erythropoietin, vascular endothelial growth factor and glycolytic enzymes (1) . Under normoxic conditions, HIF-1α is very rapidly degraded by the 26S proteasome upon ubiquitylation mediated by the von-Hippel Lindau tumor supressor protein (pVHL) (2) (3) (4) (5) (6) . Activation of transcription by the HIF-1α/Arnt dimer requires the recruitment of transcriptional coactivators such as p300/CBP and factors belonging to the p160/SRC-1 family of proteins (7) (8) (9) (10) (11) (12) . Proteins of the CBP/p300 and p160/SRC family of coactivators possess histone acetyltransferase activity and therefore have the potential to remodel chromatin structure (13, 14) . CBP and p300 are coactivator proteins that operate at the end points of a variety of signal transduction pathways, thereby modulating specific gene expression programs involved in cell growth, differentiation, homeostasis and viral
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to OPTI-MEM medium (Life Technologies) before transfection. HEK 293 cells were transfected with Lipofectamine (Life Technologies) according to the manufacturer's instructions. After transfection for 4h, medium was changed to culture medium and cells were allowed to grow for 36h at normoxia (21% O 2 ) or hypoxia (1% O 2 ). Cells were then harvested and extracts were prepared and analysed for luciferase activity.
Total protein concentration of whole cell extracts was determined by a colorimetric method (Bio-Rad).
Protein-Protein Interaction Assays-For bacterial protein expression BL-21 cells
were transformed with either pGEX-4T3 or pGEX-4T3-CH1. Protein expression and purification was performed according to routine protocols for GST gene fusion system (AmershamPharmacia). HEK 293 cells were grown in 10-cm diameter plates for 24h and transfected with 6 µg of pFLAG-GAL4/mHIF-1α(772-822) or mutants as described above. Cells were allowed to grow for 24h and then treated with 100 µM CoCl 2 or kept at normoxia for 3h. Cells were harvested and lysed in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% Sodium Deoxycolate, 1% Igepal, 0.1% SDS) containing 100 µM PMSF, 1 mM DTT and a protease inhibitor cocktail (Roche, Manheim, Germany), vortexed for 1 min followed by centrifugation at 14000 rpm for 30 min. Total protein concentration was determined as before. Five hundred µg of total proteins from whole cell extracts was used for protein-protein interaction experiments performed as follows: 30 µl gluthatione-Sepharose beads previously bound to bacterially expressed GST-CH1 were incubated with the whole cell extracts overnight at 4ºC with rotation. The pellet was washed 3 times with RIPA buffer with or without CoCl 2 and proteins were eluted by boilling in SDS-PAGE loading buffer.
The precipitated protein complex was separated by SDS-PAGE, blotted onto a nitrocellulose filter and probed with specific antibodies as described below.
Immunoblotting and Detection-Ten µg of total cell protein was blotted after separation by SDS-PAGE on a nitrocellulose filter and blocked overnight with 5%
non-fat milk in TBS. Antibodies for FLAG epitope (Sigma) or GST (AmershamPharmacia) were diluted as recommended by the manufacturer in 5% nonfat milk in TBS and incubated at room temperature for 1h. Thirty µl of a 50% slurry of Protein G-Sepharose (AmershamPharmacia) in TBS buffer (5 mM Tris, HCl pH 7.4, 150 mM NaCl) were incubated with anti-FLAG M 2 (Sigma) antibodies (diluted 1:500 in TBS) for 1h at room temperature under rotation.
After brief centrifugation the Sepharose pellets were washed two times with TBS buffer and in vitro translated proteins were added in a total volume of 50 µl in TBS and further incubated for 1h under the same conditions. After three washes with TBS, immunoprecipitated proteins were eluted with FLAG peptide (0.1 mg/ml) for 30 min at room temperature and an aliquote of the eluted material was analyzed by 7.5%
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SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by autoradiography.
Limited proteolysis was performed as previously described (32) GAL4/mHIF-1α(779-822) produced about 2-fold higher levels of relative luciferase activity both at normoxia and hypoxia, resulting in a small reduction of the hypoxic induction response to 4-fold when compared to wild-type C-TAD. In order to investigate the importance of the di-leucine repeat LL778 present in the predicted helix 1 of the C-TAD, we generated the double mutant LL778AA. The LL778-779 mutation in GAL4/mHIF-1α(772-822)(LL778AA) generated an increased transactivation activity at normoxia and hypoxia (in both cases about 2-fold above wild-type levels), again yielding slightly reduced levels of hypoxia inducibility (4.1-fold). Disruption of the predicted helix 1 of the C-TAD by deletion of the first 6 amino acids proved to have the same effect on C-TAD-mediated transactivation as point mutation of LL778-779, both manipulations resulting in an increase in activation of transcription under both normoxic and hypoxic conditions. These results are in contrast with a previously published study (35) using Hep3B cells where disruption of the predicted helix 1 by mutation of residues RLL781-783AAA within the C-TAD of hHIF-1α generated a constitutively active, non-hypoxia-responsive transactivation domain. In excellent agreement with previous reports (8, 17) GAL4/mHIF-1α(772-809) showed a dramatically reduced transactivation function both at normoxia and hypoxia, in comparison to the C-TAD (Fig. 1B) . All mutants showed equivalent levels of expression as assessed by immunoblotting using anti-FLAG antibodies (Fig. 1C) .
RESULTS

Two Predicted
In order to identify the amino acids responsible for the dramatic effect on transactivation caused by deletion of helix 2, an extensive analysis of this region of the C-TAD was performed by alanine-scanning mutagenesis (schematically represented in levels of all the mutants tested in gene reporter assays were investigated by immunoblot analysis and proven to be very comparable (data not shown).
Mutations in the Predicted Helix 2 of the C-TAD Affect Potentiation by CBP and
SRC-It has been previously demonstrated that CBP and SRC-1 are able to stimulate transcriptional activation mediated by the HIF-1α C-TAD (8, 10) , and that this potentiation effect is lost by the deletion of helix 2 which disrupts the binding to CBP (8, 20) . Against this background we next examined if the loss of transactivation function observed by mutation of the leucine residues LL808-809, LL814-815 and L818 could be Fig. 2B) . These results suggest that in the context of the GAL4/C-TAD these leucine residues within C-TAD were critical for functional interaction with CBP. In contrast, the EE812AA mutation that showed a decreased transactivation potency by itself was still responsive to CBP-or SRC-1-mediated enhancement, indicating that these acidic amino acids are not as critical as hydrophobic residues for C-TAD function.
Interaction of the C-TAD with the CH1 Domain of CBP is Affected by Specific
Mutations in Helix 2-The interaction of the HIF-1α C-TAD with the transcriptional coactivator CBP has been shown to be mediated by the CH1 domain of CBP (20) .
Based on the observation that some of the mutations in the predicted helix 2 of the C-TAD resulted in loss of transactivation even following overexpression of CBP, we investigated whether there was any correlation between the functional activity of the various C-TAD mutants and their ability to interact with the isolated CH1 domain of CBP. To this end a GST-CH1 fusion protein was used to precipitate C-TAD from whole cell extracts prepared from transiently transfected HEK 293 cells grown in the presence or absence of 100µM CoCl 2 . Fig. 3A shows the results of the GST-pull down assay analysed by immunoblotting. In control experiments, GST-CH1 did not interact with the FLAG epitope or with the GAL4 DNA binding domain under any of the tested conditions (Fig. 3A, lanes 1 and 2) . Moreover, no interaction was observed between GST and wild-type or mutant C-TAD under any of these conditions (data not shown). No significant interaction was observed between GST-CH1 and the C-TAD at normoxia (Fig. 3A, lane 3 The di-leucine repeats present in predicted helix 2 of the C-TAD were further studied to establish the relevance of each individual leucine residue for the interaction with CH1. Fig. 3B shows the results of the protein-protein interaction assay using GST-CH1 and point mutations of L808, L809, L814 and L815, respectively. As 
Mutations in the Predicted Helix 2 Mimic the Effects of Deleting the C-TAD with Regard to HIF-1α-mediated Transactivation and Interaction with Coactivators-To
establish if the leucine to alanine mutations that inactivated C-TAD function would affect mHIF-1α-mediated transactivation function we introduced the same mutations into the full length protein, thus generating mHIF-1α(LL808AA), mHIF-1α(LL814AA), and mHIF-1α(L818A), respectively. These mutants were tested for their ability to activate transcription of an HRE-driven reporter gene in HEK 293 cells (Fig. 4A) . When abilities of these CFP fusion proteins to activate transcription of an HRE-driven reporter gene corresponded to those exhibited by the FLAG-tagged chimeras and they showed similar expression levels, as assessed by immunoblot analysis using anti-GFP antibodies (data not shown). For colocalization studies we also constructed a YFP-CBP fusion protein.
The intracellular localization of the CFP and YFP fusion proteins was investigated in the absence of presence of CoCl 2 . CoCl 2 was chosen as hypoxiamimicking agent to maintain the hypoxic signal throughout the procedure, thus avoiding potential problems that may occur by reoxygenation of the samples. In these assays CFP and YFP alone were distributed throughout the cell, and CoCl 2 treatment had no effect either on the intensity or the subcellular distribution of fluorescence (data not shown). In agreement with a previous report using GFP/hHIF-1α fusion proteins (37), CFP-mHIF-1α was distributed throughout the cell at normoxia and accumulated in the nucleus upon treatment with the hypoxia-mimicking agent CoCl 2 (Fig. 5A ). The same effect was observed with CFP-mHIF-1α(532∆583) and CFP-mHIF-1α(772∆822), and introduction of helix 2 mutations into the full length protein or into CFP-mHIF-1α(532∆583) had no effect on the kinetics or quantitative aspects of CoCl 2 -inducible nuclear accumulation of any of these proteins (data not shown).
Expression of a YFP-CBP chimera in HEK 293 cells showed an exclusively nuclear protein localization exhibiting a punctuated pattern ( under any of the conditions described above (Fig. 5B) .
DISCUSSION
In the present study we have identified amino acids within the predicted helix 2 of the HIF-1α C-TAD that are essential for the hypoxia-dependent transactivation response, interaction with CBP, and intranuclear colocalization with CBP. CBP/p300
has been shown to play a critical role in cellular responses to hypoxia. Functional assays have demonstrated that CBP is able to enhance HIF-1α-mediated transactivation function, indicating that CBP functions as a coactivator in hypoxia-induced transcriptional responses (7, 8, 10, 37) . The CH1 region of p300 has been shown to interact with HIF-1α (7) by directly targeting the C-TAD, as assessed by proteinprotein interaction assays (11, 12, 20) . Based on this mechanism, overexpression of the C-TAD motif of HIF-1α was demonstrated to inhibit tumor growth in animal models, possibly by disrupting the interaction of HIF-1α with p300 (12). More recently the solution structure of the complex formed by the HIF-1α C-TAD and the CH1 domain of p300/CBP has been determined in two independent studies (30, 31) . In one of these studies the C-TAD forms three short helices upon binding to the CH1 domain (31) .
Two of the C-TAD helices identified in the solution structure overlap partially with the predicted helices described in the present study while the central helix containing N803
(hHIF-1α) was not predicted by the program and was therefore was not considered in this study.
Alanine-scanning mutagenesis of the two predicted α-helices of the C-TAD demonstrated that mutations of hydrophobic residues within helix 2 completely abrogated C-TAD-mediated transactivation, physical interaction with the isolated CH1 domain of CBP, as well as CBP-mediated enhancement of transcription. The predicted helix 2 has been reported to be essential for the interaction of HIF-1α C-TAD with the CH1 region (20) . In the solution structure of the C-TAD/CH1 complex the last helix of the C-TAD was docked in the groove of the CH1 domain, and many hydrophobic and polar interactions contribute to the stabilization of the complex (30, 31) . Two of the leucines within the predicted helix 2 that were identified in our mutation analysis have been previously shown to constitute part of the interface between HIF-1α C-TAD and the CH1 motif (L818 and L822 in hHIF-1α corresponding to L814 and L818 in mHIF-1α). In the present study we have identified three additional hydrophobic residues, I802, L808, and L815 in mHIF-1α C-TAD, that were critical for transcriptional activation by the C-TAD and interaction with CBP. In the solution structure of the complex between the C-TAD and the minimal CH1 all these amino acids were proposed to make hydrophobic and polar interactions important for stabilization of the complex.
Residues I802 and L808 are located in an intrahelix bridge while L814, L815, and L818
are present in the last helix of the C-TAD (30, 31) . Interestingly, in our study mutation of acidic residues to alanine (mutants EE812AA and D819A) decreased or abrogated hypoxia-dependent transactivation mediated by the C-TAD, but in contrast to any mutation of the hydrophobic amino acids, EE812AA and D819A were still able to interact with CH1. Moreover, transactivation by the EE812AA mutant was enhanced by CBP. Both residues E817 and D823 of hHIF-1α (corresponding to E813 and D819 in mHIF-1α) have been proposed to make electrostatic interactions with CH1 in the structural studies but do not seem to be critical for binding to CBP in our functional analysis.
It has recently been proposed that hypoxia-dependent transactivation mediated by the C-TAD is regulated by hydroxylation of N803 (N799 in mHIF-1α) by Fe(II)-2-oxoglutarate-dependent dioxygenases (28) . When mutated to alanine N803 has been shown to generate a constitutive C-TAD (28) . In contrast, mutation of N807 present in the predicted helix 2 resulted in increased transactivation activity only under hypoxic conditions. N807 has been proposed to make polar interactions with the p300 CH1 domain in one of the structural studies while in the other study the N807 was in a disordered structure (30, 31) . Based on our results N807 appears not to be critical for either transactivation or interaction with CBP.
In the present study we have visualised the in vivo interaction between HIF-1α and CBP using CFP and YFP fusion proteins. Upon coexpression of both proteins the Thus, the N-TAD, in addition to the previously described role in targeting HIF-1α for degradation at normoxia (2, 5, 21) , also contributes to the hypoxia-inducible transcriptional activation in the hypoxic cell by mediating interaction in vivo between HIF-1α and CBP, resulting in potentiation of the transactivation function of HIF-1α.
Taken together, we have identified several residues in the C-TAD that are important for hypoxia-dependent activation of transcription by HIF-1α. We have also obtained evidence that mutation of several hydrophobic residues present in a predicted α-helix of the C-TAD not only disrupts the in vitro interaction with the CH1 domain of CBP but also impairs the interaction of HIF-1α with CBP in vivo. 
